Leptomeningeal disease: current diagnostic and therapeutic strategies
PDF | HTML | How to cite
Metrics: PDF 3037 views | HTML 7550 views | ?
Gautam Nayar1,2,3, Tiffany Ejikeme1,2,3, Pakawat Chongsathidkiet1,2,6, Aladine A. Elsamadicy1,2,3, Kimberly L. Blackwell4, Jeffrey M. Clarke5, Shivanand P. Lad3 and Peter E. Fecci1,2,3,6
1Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
2The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
3Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
4Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
5Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA
6Department of Pathology, Duke University Medical Center, Durham, NC, USA
Peter E. Fecci, email: [email protected]
Keywords: leptomeningeal disease, neoplastic meningitis, leptomeningeal carcinomatosis, intrathecal chemotherapy, radiation therapy
Received: May 10, 2017 Accepted: July 20, 2017 Published: August 16, 2017
Leptomeningeal disease has become increasingly prevalent as novel therapeutic interventions extend the survival of cancer patients. Although a majority of leptomeningeal spread occurs secondary to breast cancer, lung cancer, and melanoma, a wide variety of malignancies have been reported as primary sources. Symptoms on presentation are equally diverse, often involving a combination of neurological deficits with the possibility of obstructive hydrocephalus. Diagnosis is definitively made via cerebrospinal fluid cytology for malignant cells, but neuro-imaging with high quality T1-weighted magnetic resonance imaging can aid diagnosis and localization. While leptomeningeal disease is still a terminal, late-stage complication, a variety of treatment modalities, such as intrathecal chemotherapeutics and radiation therapy, have improved median survival from 4–6 weeks to 3–6 months. Positive prognosticative factors for survival include younger age, high performance scores, and controlled systemic disease. In looking to the future, diagnostics that improve early detection and chemotherapeutics tailored to the primary malignancy will likely be the most significant advances in improving survival.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.